Ritonavir boosting is not the solution—it’s the problem.
Ritonavir boosting isn't the only problem with RG7227. I would prefer to see Roche use lower doses of RG7227 without boosting in INFORM-3, with the option of licensing a guanine nuke if needed, to boost the potency and/or resistance profile of the existing combination. It's easy to overlook the potential of this DAA, which may be the first to market, by focusing too much on the weaker half.
Market Data 
Markets 
AI
